{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+A&page=7",
    "query": {
      "intervention": "High Dose Drug A",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 1664,
    "total_pages": 167,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+A&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+A&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T17:33:30.785Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00301418",
      "title": "Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma"
      ],
      "interventions": [
        {
          "name": "Erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2006-03",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2016-02-10",
      "last_synced_at": "2026-11-07T17:33:30.785Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00301418"
    },
    {
      "nct_id": "NCT01846208",
      "title": "Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Food Allergy"
      ],
      "interventions": [
        {
          "name": "Egg Oral Immunotherapy",
          "type": "DRUG"
        },
        {
          "name": "Baked Egg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hugh A Sampson, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "3 Years to 16 Years"
      },
      "enrollment_count": 92,
      "start_date": "2013-07",
      "completion_date": "2018-09-30",
      "has_results": true,
      "last_update_posted_date": "2019-07-26",
      "last_synced_at": "2026-11-07T17:33:30.785Z",
      "location_count": 5,
      "location_summary": "Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01846208"
    },
    {
      "nct_id": "NCT01576718",
      "title": "A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fp MDPI",
          "type": "DRUG"
        },
        {
          "name": "Placebo MDPI",
          "type": "OTHER"
        },
        {
          "name": "Flovent Diskus",
          "type": "DRUG"
        },
        {
          "name": "albuterol/salbutamol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 889,
      "start_date": "2012-04",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2018-05-08",
      "last_synced_at": "2026-11-07T17:33:30.785Z",
      "location_count": 148,
      "location_summary": "Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01576718"
    },
    {
      "nct_id": "NCT03005717",
      "title": "Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Submental Fat"
      ],
      "interventions": [
        {
          "name": "LIPO-202",
          "type": "DRUG"
        },
        {
          "name": "Placebo for LIPO-202",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neothetics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 162,
      "start_date": "2016-12-22",
      "completion_date": "2017-06-02",
      "has_results": false,
      "last_update_posted_date": "2017-10-20",
      "last_synced_at": "2026-11-07T17:33:30.785Z",
      "location_count": 11,
      "location_summary": "Beverly Hills, California • Manhattan Beach, California • Greenwood Village, Colorado + 8 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Manhattan Beach",
          "state": "California"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Warren",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03005717"
    },
    {
      "nct_id": "NCT01273376",
      "title": "Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "RX-10100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rexahn Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 314,
      "start_date": "2010-12",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2013-11-19",
      "last_synced_at": "2026-11-07T17:33:30.785Z",
      "location_count": 44,
      "location_summary": "Cerritos, California • Escondido, California • Los Angeles, California + 38 more",
      "locations": [
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01273376"
    },
    {
      "nct_id": "NCT03066115",
      "title": "Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypoxia",
        "Hypercapnia"
      ],
      "interventions": [
        {
          "name": "L-NMMA",
          "type": "DRUG"
        },
        {
          "name": "Ketorolac",
          "type": "DRUG"
        },
        {
          "name": "Ascorbic Acid",
          "type": "DRUG"
        },
        {
          "name": "Intravenous Catheter",
          "type": "PROCEDURE"
        },
        {
          "name": "Transcranial Doppler Ultrasound",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-12-01",
      "completion_date": "2021-12-01",
      "has_results": false,
      "last_update_posted_date": "2019-01-10",
      "last_synced_at": "2026-11-07T17:33:30.785Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03066115"
    },
    {
      "nct_id": "NCT05303220",
      "title": "A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Branebrutinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 56,
      "start_date": "2022-04-08",
      "completion_date": "2022-08-18",
      "has_results": false,
      "last_update_posted_date": "2023-02-15",
      "last_synced_at": "2026-11-07T17:33:30.785Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05303220"
    },
    {
      "nct_id": "NCT06600880",
      "title": "Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease, Early Onset"
      ],
      "interventions": [
        {
          "name": "Neuronavigation-guided single-element focused ultrasound transducer",
          "type": "DEVICE"
        },
        {
          "name": "Lumason",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography (PET)",
          "type": "RADIATION"
        },
        {
          "name": "Amyvid",
          "type": "DRUG"
        },
        {
          "name": "MK-6240",
          "type": "DRUG"
        },
        {
          "name": "Dotarem",
          "type": "DRUG"
        },
        {
          "name": "Blood draw",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "UR5e",
          "type": "DEVICE"
        },
        {
          "name": "Urine test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "OTHER",
        "RADIATION",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2027-08",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-11-07T17:33:30.785Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06600880"
    },
    {
      "nct_id": "NCT05202327",
      "title": "PDC-1421 Treatment in Adult Patients With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Attention-Deficit Hyperactivity Disorder (ADHD)"
      ],
      "interventions": [
        {
          "name": "PDC-1421 Capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioLite, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 99,
      "start_date": "2022-04-07",
      "completion_date": "2024-04-08",
      "has_results": true,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-11-07T17:33:30.785Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05202327"
    },
    {
      "nct_id": "NCT05766735",
      "title": "Treating Early Type 2 Diabetes by Reducing Postprandial Glucose Excursions: A Paradigm Shift in Lifestyle Modification",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Routine Care + Glycemic Excursion Minimization (RC+GEM)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Routine Care (RC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Chiara Fabris, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 200,
      "start_date": "2023-08-08",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-11-07T17:33:30.785Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05766735"
    }
  ]
}